Carlos Teixeira, CEO of Teva Spain and Portugal, discusses the challenges the generic sector is facing in Spain, which ultimately spurred the company towards other business opportunities, and highlights the significant footprint of the Spanish affiliate, with its manufacturing site in Zaragoza serving as an export base for Europe and South America.
Carlos, you joined Teva’s Portuguese affiliate in 2007 and as of 2015 you are CEO at Teva for Spain and Portugal. What were the specificities you had to adapt to?
"Last but not least, positive discrimination should be reintegrated into Spanish law. In the years to come, nobody will invest in the production of generics if the only purpose is to cut down prices. "
